Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

Similar articles for PubMed (Select 22094280)

1.

Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases.

Nitsche C, Steuer C, Klein CD.

Bioorg Med Chem. 2011 Dec 15;19(24):7318-37. doi: 10.1016/j.bmc.2011.10.061. Epub 2011 Oct 25.

PMID:
22094280
2.

Inhibition of Dengue virus and West Nile virus proteases by click chemistry-derived benz[d]isothiazol-3(2H)-one derivatives.

Tiew KC, Dou D, Teramoto T, Lai H, Alliston KR, Lushington GH, Padmanabhan R, Groutas WC.

Bioorg Med Chem. 2012 Feb 1;20(3):1213-21. doi: 10.1016/j.bmc.2011.12.047. Epub 2011 Dec 30.

3.

Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases.

Lai H, Dou D, Aravapalli S, Teramoto T, Lushington GH, Mwania TM, Alliston KR, Eichhorn DM, Padmanabhan R, Groutas WC.

Bioorg Med Chem. 2013 Jan 1;21(1):102-13. doi: 10.1016/j.bmc.2012.10.058. Epub 2012 Nov 15.

4.

Inhibitors of Dengue virus and West Nile virus proteases based on the aminobenzamide scaffold.

Aravapalli S, Lai H, Teramoto T, Alliston KR, Lushington GH, Ferguson EL, Padmanabhan R, Groutas WC.

Bioorg Med Chem. 2012 Jul 1;20(13):4140-8. doi: 10.1016/j.bmc.2012.04.055. Epub 2012 May 10.

5.

Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease.

Schüller A, Yin Z, Brian Chia CS, Doan DN, Kim HK, Shang L, Loh TP, Hill J, Vasudevan SG.

Antiviral Res. 2011 Oct;92(1):96-101. doi: 10.1016/j.antiviral.2011.07.002. Epub 2011 Jul 8.

PMID:
21763725
6.

Small molecule pan-dengue and West Nile virus NS3 protease inhibitors.

Cregar-Hernandez L, Jiao GS, Johnson AT, Lehrer AT, Wong TA, Margosiak SA.

Antivir Chem Chemother. 2011 May 12;21(5):209-17. doi: 10.3851/IMP1767.

7.

Synthesis and biological evaluation of α-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture.

Steuer C, Gege C, Fischl W, Heinonen KH, Bartenschlager R, Klein CD.

Bioorg Med Chem. 2011 Jul 1;19(13):4067-74. doi: 10.1016/j.bmc.2011.05.015. Epub 2011 May 18.

PMID:
21641807
8.

A FRET-based assay for the discovery of West Nile Virus NS2B-NS3 protease inhibitors.

Adamek RN, Maniquis RV, Khakoo S, Bridges MD, Salzameda NT.

Bioorg Med Chem Lett. 2013 Sep 1;23(17):4848-50. doi: 10.1016/j.bmcl.2013.06.081. Epub 2013 Jul 4.

PMID:
23886689
9.

Structure-guided fragment-based in silico drug design of dengue protease inhibitors.

Knehans T, Schüller A, Doan DN, Nacro K, Hill J, Güntert P, Madhusudhan MS, Weil T, Vasudevan SG.

J Comput Aided Mol Des. 2011 Mar;25(3):263-74. doi: 10.1007/s10822-011-9418-0. Epub 2011 Feb 23.

PMID:
21344277
10.

Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases.

Ganesh VK, Muller N, Judge K, Luan CH, Padmanabhan R, Murthy KH.

Bioorg Med Chem. 2005 Jan 3;13(1):257-64.

PMID:
15582469
11.

West Nile Virus NS2B/NS3 protease as an antiviral target.

Chappell KJ, Stoermer MJ, Fairlie DP, Young PR.

Curr Med Chem. 2008;15(27):2771-84. Review.

PMID:
18991636
12.

Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease.

Nitsche C, Behnam MA, Steuer C, Klein CD.

Antiviral Res. 2012 Apr;94(1):72-9. doi: 10.1016/j.antiviral.2012.02.008. Epub 2012 Feb 26.

PMID:
22391061
13.

Small molecule drug discovery for Dengue and West Nile viruses: applying experience from hepatitis C virus.

Parkinson T, Pryde DC.

Future Med Chem. 2010 Jul;2(7):1181-203. doi: 10.4155/fmc.10.195. Review. Erratum in: Future Med Chem. 2011 Apr;3(6):770.

PMID:
21426163
14.

Discovery, synthesis, and in vitro evaluation of West Nile virus protease inhibitors based on the 9,10-dihydro-3H,4aH-1,3,9,10a-tetraazaphenanthren-4-one scaffold.

Samanta S, Cui T, Lam Y.

ChemMedChem. 2012 Jul;7(7):1210-6. doi: 10.1002/cmdc.201200136. Epub 2012 Apr 30.

PMID:
22550001
15.

HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus.

Johnston PA, Phillips J, Shun TY, Shinde S, Lazo JS, Huryn DM, Myers MC, Ratnikov BI, Smith JW, Su Y, Dahl R, Cosford ND, Shiryaev SA, Strongin AY.

Assay Drug Dev Technol. 2007 Dec;5(6):737-50. doi: 10.1089/adt.2007.101.

PMID:
18181690
16.
17.

Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease.

Hammamy MZ, Haase C, Hammami M, Hilgenfeld R, Steinmetzer T.

ChemMedChem. 2013 Feb;8(2):231-41. doi: 10.1002/cmdc.201200497. Epub 2013 Jan 10.

PMID:
23307694
18.

Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction.

Wichapong K, Pianwanit S, Sippl W, Kokpol S.

J Mol Recognit. 2010 May-Jun;23(3):283-300. doi: 10.1002/jmr.977.

PMID:
19693793
19.

Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus.

Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, Lim SP, Yin Z, Keller TH, Vasudevan SG, Hommel U.

Nat Struct Mol Biol. 2006 Apr;13(4):372-3. Epub 2006 Mar 12.

PMID:
16532006
20.

Characterization of the West Nile virus protease substrate specificity and inhibitors.

Mueller NH, Yon C, Ganesh VK, Padmanabhan R.

Int J Biochem Cell Biol. 2007;39(3):606-14. Epub 2006 Nov 23.

PMID:
17188926
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk